Autonomix Medical Shares Rise After Positive Trial for Pancreatic Cancer Pain Treatment

Dow Jones

2024/10/31

By Chris Wack

Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer.

The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain.

Autonomix said it remains on track to complete enrollment by calendar year end.

Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit.

A total of twenty patients will be enrolled in the trial.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 31, 2024 09:54 ET (13:54 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479038014"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479038014\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479038014?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479038014","market":"sh","top_or_hot":-1,"title":"Autonomix Medical Shares Rise After Positive Trial for Pancreatic Cancer Pain Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer. \n</p>\n<p>\n  The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain. \n</p>\n<p>\n  Autonomix said it remains on track to complete enrollment by calendar year end. \n</p>\n<p>\n  Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit. \n</p>\n<p>\n  A total of twenty patients will be enrolled in the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2024 09:54 ET (13:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Autonomix Medical Shares Rise After Positive Trial for Pancreatic Cancer Pain Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAutonomix Medical Shares Rise After Positive Trial for Pancreatic Cancer Pain Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-10-31 21:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer. \n</p>\n<p>\n  The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain. \n</p>\n<p>\n  Autonomix said it remains on track to complete enrollment by calendar year end. \n</p>\n<p>\n  Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit. \n</p>\n<p>\n  A total of twenty patients will be enrolled in the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2024 09:54 ET (13:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479038014","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479038014","pubTimestamp":1730382840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer.The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain.Autonomix said it remains on track to complete enrollment by calendar year end.Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit.A total of twenty patients will be enrolled in the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","AMIX":"Autonomix Medical Inc"},"translate_title":"胰腺癌疼痛治疗试验取得积极成果后，Autonomix Medical股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMIX":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer. \n\n\n  The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain. \n\n\n  Autonomix said it remains on track to complete enrollment by calendar year end. \n\n\n  Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit. \n\n\n  A total of twenty patients will be enrolled in the trial. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 09:54 ET (13:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}